未登录 分享 收藏
分享 收藏
分享 收藏
Ribociclib plus Endocrine Therapy in Early Breast Cancer Slamon, Dennis; Lipatov, Oleg; Nowecki, Zbigniew; McAndrew, Nicholas; Kukielka-Budny, Bozena; Stroyakovskiy, Daniil; Yardley, Denise A.; Huang, Chiun-Sheng; Fasching, Peter A.; Crown, John; Bardia, Aditya; Chia, Stephen; Im, Seock-Ah; Ruiz-Borrego, Manuel; Loi, Sherene; Xu, Binghe; Hurvitz, Sara; Barrios, Carlos; Untch, Michael; Moroose, Rebecca; Visco, Frances; Afenjar, Karen; Fresco, Rodrigo; Severin, Irene; Ji, Yan; Ghaznawi, Farhat; Li, Zheng; Zarate, Juan P.; Chakravartty, Arunava; Taran, Tetiana; Hortobagyi, Gabriel 分享 收藏
Methodology for Good Machine Learning with Multi-Omics Data Coroller, Thibaud; Sahiner, Berkman; Amatya, Anup; Gossmann, Alexej; Karagiannis, Konstantinos; Moloney, Conor; Samala, Ravi K.; Santana-Quintero, Luis; Solovieff, Nadia; Wang, Craig; Amiri-Kordestani, Laleh; Cao, Qian; Cha, Kenny H.; Charlab, Rosane; Cross, Frank H.; Hu, Tingting; Huang, Ruihao; Kraft, Jeffrey; Krusche, Peter; Li, Yutong; Li, Zheng; Mazo, Ilya; Paul, Rahul; Schnakenberg, Susan; Serra, Paolo; Smith, Sean; Song, Chi; Su, Fei; Tiwari, Mohit; Vechery, Colin; Xiong, Xin; Zarate, Juan Pablo; Zhu, Hao; Chakravartty, Arunava; Liu, Qi; Ohlssen, David; Petrick, Nicholas; Schneider, Julie A.; Walderhaug, Mark; Zuber, Emmanuel 分享 收藏
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant Neven, P.; Fasching, P. A.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S. -a.; Petrakova, K.; Bianchi, G. V.; Martin, M.; Nusch, A.; Sonke, G. S.; de la Cruz-merino, L.; Beck, J. T.; Zarate, J. P.; Wang, Y.; Chakravartty, A.; Wang, C.; Slamon, D. J. 分享 收藏
Potential value of ctDNA monitoring in metastatic HR + /HER2-breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial Chiu, Joanne; Su, Fei; Joshi, Mukta; Masuda, Norikazu; Ishikawa, Takashi; Aruga, Tomoyuki; Zarate, Juan Pablo; Babbar, Naveen; Balbin, O. Alejandro; Yap, Yoon-Sim 分享 收藏
Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR+/HER2-early breast cancer NATALEE的基本原理和试验设计: 在HR /HER2-early乳腺癌患者中，辅助ribociclib加内分泌治疗与单独内分泌治疗的III期试验 Slamon, Dennis J.; Fasching, Peter A.; Hurvitz, Sara; Chia, Stephen; Crown, John; Martin, Miguel; Barrios, Carlos H.; Bardia, Aditya; Im, Seock-Ah; Yardley, Denise A.; Untch, Michael; Huang, Chiun-Sheng; Stroyakovskiy, Daniil; Xu, Binghe; Moroose, Rebecca L.; Loi, Sherene; Visco, Frances; Bee-Munteanu, Valerie; Afenjar, Karen; Fresco, Rodrigo; Taran, Tetiana; Chakravartty, Arunava; Zarate, Juan Pablo; Lteif, Agnes; Hortobagyi, Gabriel N. 分享 收藏
Pooled analysis of post-progression treatments after first-line ribociclib plus endocrine therapy in patients with HR+/HER2-advanced breast cancer in the MONALEESA-2,-3, and-7 studies Hamilton, Erika; Spring, Laura M.; Fasching, Peter A.; Franco, Sandra; DeBoer, Richard H.; Cortes, Javier; Kalinsky, Kevin; Juric, Dejan; Bardia, Aditya; Haftchenary, Sina; Lteif, Agnes; Zarate, Juan Pablo; Cen, Liyi; Neven, Patrick 分享 收藏
Pooled exploratory analysis of survival in patients (pts) with HR+/HER2-advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) trials Yardley, D. A.; Yap, Y. S.; Azim, H. A.; De Boer, R. H.; Campone, M.; Ring, A.; De laurentiis, M.; O'Shaughnessy, J.; Cortes, J.; Chattar, Y.; Thuerigen, A.; Zarate, J. P.; Nusch, A. 分享 收藏
Correlative analysis of overall survival by intrinsic subtype across the MONALEESA-2,-3, and-7 studies of ribociclib plus endocrine therapy in patients with HR+/HER2-advanced breast cancer Carey, Lisa; Solovieff, Nadia; Andre, Fabrice; O'Shaughnessy, Joyce; Cameron, David A.; Janni, Wolfgang; Sonke, Gabe S.; Yap, Yoon-Sim; Yardley, Denise A.; Zarate, Juan Pablo; Taran, Tetiana; Su, Faye; Lteif, Agnes; Prat, Aleix 分享 收藏
Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib plus letrozole in postmenopausal patients with advanced HR+/HER2-breast cancer O'Shaughnessy, Joyce; Stemmer, Salomon M.; Burris, Howard A.; Yap, Yoon-Sim; Sonke, Gabe; Hart, Lowell; Campone, Mario; Petrakova, Katarina; Winer, Eric P.; Janni, Wolfgang; Conte, Pierfranco; Cameron, David A.; Andre, Fabrice; Arteaga, Carlos; Zarate, Juan Pablo; Chakravartty, Arunava; Taran, Tetiana; Le Gac, Fabienne; Serra, Paolo; Hortobagyi, Gabriel N. 分享 收藏
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (vol 32, pg 1015, 2021) Slamon, D. J.; Neven, P.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.; Petrakova, K.; Bianchi, G. Valeria; Martin, M.; Nusch, A.; Sonke, G. S.; De la Cruz-Merino, L.; Beck, J. T.; Ji, Y.; Wang, C.; Deore, U.; Chakravartty, A.; Zarate, J. P.; Taran, T.; Fasching, P. A. 分享 收藏
Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2L) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) Hortobagyi, G. N.; Stemmer, S. M.; Burris, H. A., III; Yap, Y. S.; Sonke, G. S.; Hart, L.; Campone, M.; Petrakova, K.; Winer, E. P.; Janni, W.; Conte, P. F.; Cameron, D.; Andre, F.; Arteaga, C.; Zarate, J. P.; Chakravartty, A.; Taran, T.; Le Gac, F.; Serra, P.; O'Shaughnessy, J. 分享 收藏
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival 瑞博西尼联合氟维司群治疗激素受体阳性、人表皮生长因子受体2阴性晚期乳腺癌绝经后妇女的III期随机MONALEESA-3试验: 更新的总生存期 Slamon, D. J.; Neven, P.; Chia, S.; Jerusalem, G.; De Laurentiis, M.; Im, S.; Petrakova, K.; Bianchi, G. Valeria; Martin, M.; Nusch, A.; Sonke, G. S.; De la Cruz-Merino, L.; Beck, J. T.; Ji, Y.; Wang, C.; Deore, U.; Chakravartty, A.; Zarate, J. P.; Taran, T.; Fasching, P. A. 分享 收藏
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2,-3 and-7 trials in hormone receptor-positive, HER2-negative advanced breast cancer Burris, Howard A.; Chan, Arlene; Bardia, Aditya; Thaddeus Beck, J.; Sohn, Joohyuk; Neven, Patrick; Tripathy, Debu; Im, Seock-Ah; Chia, Stephen; Esteva, Francisco J.; Hart, Lowell; Zarate, Juan Pablo; Ridolfi, Antonia; Lorenc, Karen Rodriguez; Yardley, Denise A. 分享 收藏
Overall survival (OS) results by age subgroup from the phase III MONALEESA-7 (ML-7) trial of premenopausal patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) Lu, Y-S.; El Saghir, N. S.; Hurvitz, S. A.; Tripathy, D.; Cardoso, F.; Colleoni, M. A.; Campos-Gomez, S.; Franke, F. A.; Oregan, R.; Wang, C.; Wang, Y.; Zarate, J. P.; Chakravartty, A.; Im, S-A. 分享 收藏
Updated results from the Canadian sub-population of the phase IIIb CompLEEment-1 ribociclib plus letrozole HR+HER2-advanced breast cancer trial Califaretti, N.; Ferrario, C.; Warner, E.; Joy, A. A.; Chia, S. K. L.; Wu, J.; Zarate, J. P.; Menon-Singh, L.; Leite, R. A.; Haftchenary, S.; Perri, S. R.; Dent, S. F. 分享 收藏
Real-world effectiveness of alpelisib (ALP) plus fulvestrant (FUL) compared with standard treatment among patients (Pts) with hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2 negative (HER2-) PIK3CA-mutated (Mut) advanced breast cancer (ABC) Turner, S.; Chia, S. K. L.; Kanakamedala, H.; Hsu, W-C.; Park, J.; Chandiwana, D.; Ridolfi, A.; Yu, C-L.; Zarate, J. P.; Rugo, H. S. 分享 收藏
.png){kind=icon}
.png){kind=icon}
.png)
ANNALS OF ONCOLOGY.png)
OAAI
.png){kind=icon}
分享.png){kind=icon}
收藏